Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Chelidonine |
Synonyms | |
Therapy Description |
Chelidonine is a naturally occurring plant alkaloid that has been show to possess anti-inflammatory properties (PMID: 29044876), and may results in inhibition of Nras, p38-p53, and PI3K signaling (PMID: 32156748, PMID: 22979935), potentially leading to inhibition of tumor growth and cancer cell killing (PMID: 26677104, PMID: 32156748). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Chelidonine | Chelidonine is a naturally occurring plant alkaloid that has been show to possess anti-inflammatory properties (PMID: 29044876), and may results in inhibition of Nras, p38-p53, and PI3K signaling (PMID: 32156748, PMID: 22979935), potentially leading to inhibition of tumor growth and cancer cell killing (PMID: 26677104, PMID: 32156748). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | melanoma | sensitive | Chelidonine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Chelidonine treatment inhibited activation of Nras and downstream signaling pathways, reduced proliferation and colony formation, and induced apoptosis in melanoma cells harboring NRAS Q61L in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 32156748). | 32156748 |
NRAS Q61R | melanoma | sensitive | Chelidonine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Chelidonine treatment inhibited activation of Nras and downstream signaling pathways, reduced proliferation and colony formation, and induced apoptosis in melanoma cells harboring NRAS Q61R in culture, and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 32156748). | 32156748 |
NRAS Q61K | melanoma | sensitive | Chelidonine | Preclinical - Cell culture | Actionable | In a preclinical study, Chelidonine treatment inhibited activation of Nras and downstream signaling pathways, reduced proliferation and colony formation, and induced apoptosis in melanoma cells harboring NRAS Q61K in culture (PMID: 32156748). | 32156748 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|